A muscle-preservation trial tests what is lost alongside tirzepatide weight

What happened

The EMBRAZE phase 2 trial asked a practical question created by incretin-based weight loss: can an added therapy preserve lean tissue while total body weight falls? Investigators randomized 102 adults with overweight or obesity to tirzepatide plus apitegromab or tirzepatide plus placebo.

What the study found

At 24 weeks, the apitegromab group lost an estimated 1.9 kilograms less lean mass than the placebo group while total weight loss remained similar. The authors calculated 54.9% relative retention of lean mass. Overall adverse-event incidence was similar between groups, and one serious adverse event occurred in each arm.

Evidence check

Apitegromab is a monoclonal antibody against myostatin activation, not a peptide drug, but the trial directly addresses body-composition effects during tirzepatide peptide therapy. The study used an 80% confidence interval and lasted 24 weeks. It did not establish that the measured lean-mass difference improves strength, mobility, frailty risk or long-term outcomes.

Why it matters

Scale weight alone is an incomplete treatment endpoint, especially for older adults or people with limited muscle reserve. The result makes functional outcomes—not only imaging-derived composition—an essential next test. It does not justify adding an investigational antibody to routine incretin treatment.